- Home
- KAR vs KROS Comparison
KAR vs KROS Comparison
Compare KAR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAR
- KROS
- Stock Information
- Founded
- KAR 2006
- KROS 2015
- Country
- KAR United States
- KROS United States
- Employees
- KAR N/A
- KROS N/A
- Industry
- KAR Retail-Auto Dealers and Gas Stations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- KAR Consumer Discretionary
- KROS Health Care
- Exchange
- KAR Nasdaq
- KROS Nasdaq
- Market Cap
- KAR 1.9B
- KROS 1.8B
- IPO Year
- KAR 2009
- KROS 2020
- Fundamental
- Price
- KAR $19.86
- KROS $56.62
- Analyst Decision
- KAR Buy
- KROS Strong Buy
- Analyst Count
- KAR 4
- KROS 8
- Target Price
- KAR $20.25
- KROS $91.43
- AVG Volume (30 Days)
- KAR 686.2K
- KROS 383.1K
- Earning Date
- KAR 11-06-2024
- KROS 11-06-2024
- Dividend Yield
- KAR N/A
- KROS N/A
- EPS Growth
- KAR N/A
- KROS N/A
- EPS
- KAR 0.19
- KROS N/A
- Revenue
- KAR $1,687,800,000.00
- KROS $651,000.00
- Revenue This Year
- KAR $4.74
- KROS $1,232.45
- Revenue Next Year
- KAR $4.64
- KROS $126.39
- P/E Ratio
- KAR $108.14
- KROS N/A
- Revenue Growth
- KAR 3.76
- KROS 8037.50
- 52 Week Low
- KAR $12.86
- KROS $27.31
- 52 Week High
- KAR $20.45
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- KAR 72.53
- KROS 38.94
- Support Level
- KAR $15.83
- KROS $65.54
- Resistance Level
- KAR $20.45
- KROS $70.26
- Average True Range (ATR)
- KAR 0.58
- KROS 3.17
- MACD
- KAR 0.34
- KROS -0.64
- Stochastic Oscillator
- KAR 87.34
- KROS 9.07
About KAR OPENLANE Inc.
Openlane Inc offers a digital marketplace for used vehicles. The services comprise financing, repossessions, repairs, transportation, warranty, and inventory services. It operates used-vehicle auctions and offers complete online services for all parties involved. The company has two operating segments which include Marketplace and Finance, of which it generates the majority of the revenue from the Marketplace segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.